Although the data from phase I/II trials of TCN‐PM therapy in advanced hematologic malignancies patients are encouraging, the clinical advance of TCN‐PM is limited due to the variable AKT activities in AML patients and the lack of biomarker for drug sensitivity. This evidence concerns the gene AKT1 and acute myeloid leukemia.